Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Nifty Pharma
Nifty Pharma Performance
Day's Range
Low
₹25,878.20
High
₹26,102.40
52 Week Range
Low
₹21,149.90
High
₹26,135.75
| Previous Close | ₹26,003.15 |
|---|---|
| Day's Range | ₹25,878.20 - ₹26,102.40 |
| Open | ₹26,007.20 |
| 52 Week Range | ₹21,149.90 - ₹26,135.75 |
| Volume | 2,39,85,785 |
Nifty Pharma Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| Cipla Ltd. | 1432.40 |  -9.20 (-0.64%) |
Healthcare |
| Dr. Reddy's Laboratories Ltd. | 1211.40 | -11.70 (-0.96%) |
Healthcare |
| Lupin Ltd. | 2510.90 |  32.40 (1.31%) |
Healthcare |
| Torrent Pharmaceuticals Ltd. | 5044.10 | 38.70 (0.77%) |
Healthcare |
| Abbott India Ltd. | 28750.00 | 475.00 (1.68%) |
Healthcare |
| Ipca Laboratories Ltd. | 1799.80 | -38.80 (-2.11%) |
Healthcare |
| Sun Pharmaceutical Industries Ltd. | 1961.30 | 4.90 (0.25%) |
Healthcare |
| Aurobindo Pharma Ltd. | 1578.60 | 19.00 (1.22%) |
Healthcare |
| Glenmark Pharmaceuticals Ltd. | 2241.50 | 2.00 (0.09%) |
Healthcare |
| Wockhardt Ltd. | 1900.30 | -23.10 (-1.20%) |
Healthcare |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 24188.2 | 26373.20 | 22182.55 |
| Nifty IT | 28987.95 | 40301.40 | 25699.10 |
| Nifty Next 50 | 72549.9 | 73141.05 | 59896.10 |
| NIFTY50 USD Index | 8718.3 | 10443.40 | 8132.40 |
| Nifty Bank | 57910.75 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 62951.6 | 63183.35 | 52032.85 |
| Nifty 500 | 23340.55 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 18092.3 | 18114.45 | 14804.55 |
| Nifty 100 | 25249.35 | 26975.15 | 22720.45 |
| Nifty FMCG | 48836.55 | 58485.05 | 45334.15 |
Latest News
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Lupin informs about acquisition
Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Lupin has informed that Lupin Inc. U.S.A., wholly owned subsidiary of the Company, has entered into a licensing agreement to grant an exclusive perpetual license for two of its oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), to Kaveri Therapeutics, Inc. U.S.A. (‘Kaveri’), in exchange for an 82.2% equity stake (Common Shares) in Kaveri. The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026), along with other applicable circulars, are set out in Annexure I. A press release regarding this arrangement is enclosed.
The above information is a part of company’s filings submitted to BSE.
Ajanta Pharma informs about conference call
Ajanta Pharma informs about board meeting
With reference to its letter dated 20th July 2026, informing about the Board meeting scheduled on Thursday, 30th July 2026 to consider and take on record the unaudited financial results for the first quarter ended 30th June 2026. Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, Ajanta Pharma has informed that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2027; and b. fixation of Wednesday, 5th August 2026 as the Record Date for the payment of interim dividend, if declared.
The above information is a part of company’s filings submitted to BSE.
Divi's Laboratories informs about board meeting
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of NIFTYPHARMA index is ₹26092.5 as of 2026-07-21.
The total volume of NIFTYPHARMA index is 23985785.00 as of 2026-07-21.
The percentage change in value of NIFTYPHARMA index is 0.34% as of 2026-07-21.
The absolute increase in NIFTYPHARMA index value since the previous trading day is ₹89.35 as of 2026-07-21.
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
